Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: Efficacy and safety from a phase IIa randomised multicentre study

Gut

Volumn 64, Issue 6, 2015, Pages 894-900

  Reinisch, Walter ^a,b   Panés, Julián ^c   Khurana, Sunil ^d   Toth, Gabor ^e   Hua, Fei ^f   Comer, Gail M ^f   Hinz, Michelle ^f   Page, Karen ^f   O'Toole, Margot ^f   Moorehead, Tara McDonnell ^g   Zhu, Hua ^f   Sun, YanHui ^f   Cataldi, Fabio ^f  

^a MCMASTER UNIVERSITY   (Canada)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d Premier Medical Group   (United States)

^e ST JOHN'S HOSPITAL   (Hungary)

^f PFIZER INC   (United States)

^g SYNEOS HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANRUKINZUMAB; CALGRANULIN; CYTOKINE; INTERLEUKIN 13; MONOCLONAL ANTIBODY; PLACEBO; ANRUKINZUMAB, HUMAN; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN-13, HUMAN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; FECES LEVEL; FEMALE; HEADACHE; HEALING; HUMAN; INTENTION TO TREAT ANALYSIS; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MUCOSA; MULTICENTER STUDY; NAUSEA; PATIENT DROPOUTS; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; ADOLESCENT; ANALYSIS OF VARIANCE; ANTAGONISTS AND INHIBITORS; BIOPSY; BLOOD; CHEMISTRY; CLINICAL TRIAL; COLITIS, ULCERATIVE; COLON; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; EOSINOPHIL; FECES; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; BIOPSY; COLITIS, ULCERATIVE; COLON; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EOSINOPHILS; FECES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-13; LEUKOCYTE COUNT; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; REMISSION INDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84935030329     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308337     Document Type: Article

References (11)

1. Mannon P, Reinisch W. Interleukin 13 and its role in gut defence and inflammation. Gut 2012;61:1765-73.
2. Inoue S, Matsumoto T, Iida M, et al. Characterization of cytokine expression in the rectal mucosa of ulcerative colitis: correlation with disease activity. Am J Gastroenterol 1999;94:2441-6.
3. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004;113:1490-7.
4. Zurawski SM, Chomarat P, Djossou O, et al. The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor. J Biol Chem 1995;270:13869-78.
5. Hershey GK. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol 2003;111:677-90; quiz 91.
6. Mandal D, Levine AD. Elevated IL-13Ralpha2 in intestinal epithelial cells from ulcerative colitis or colorectal cancer initiates MAPK pathway. Inflamm Bowel Dis 2010;16:753-64.
7. Arima K, Umeshita-Suyama R, Sakata Y, et al. Upregulation of IL-13 concentration in vivo by the IL13 variant associated with bronchial asthma. J Allergy Clin Immunol 2002;109:980-7.
8. Bree A, Schlerman FJ, Wadanoli M, et al. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol 2007;119:1251-7.
9. Kasaian MT, Donaldson DD, Tchistiakova L, et al. Efficacy of IL-13 neutralization in a sheep model of experimental asthma. Am J Respir Cell Mol Biol 2007;36:368-76.
10. Kasaian MT, Tan XY, Jin M, et al. Interleukin-13 neutralization by two distinct receptor blocking mechanisms reduces immunoglobulin E responses and lung inflammation in cynomolgus monkeys. J Pharmacol Exp Ther 2008;325:882-92.
11. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9.